← Back to Search

Geriatric Co-Management for Gastrointestinal Cancer (REACH Trial)

N/A

Recruiting

Led By Nadine J McCleary, MD, MPH

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with a gastrointestinal cancer, including: cancers of the esophagus, stomach, pancreas, liver, bile duct, ampulla, colon, rectum, or anus, as well as neuroendocrine tumors.

Patients who are age 70+ at time of initial consult at DF/BWCC

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

REACH Trial Summary

This trial is testing how cancer care consultation with a geriatrician can improve outcomes for older adults with gastrointestinal malignancies.

Who is the study for?

This trial is for adults aged 70 or older who have been diagnosed with gastrointestinal cancers such as esophageal, stomach, pancreatic, liver, bile duct, ampulla, colon, rectum or anus cancer. They must be continuing care at DF/BWCC and speak English or Spanish.Check my eligibility

What is being tested?

The REACH study is testing the effectiveness of geriatric co-management in improving health outcomes for elderly patients with various types of gastrointestinal cancers during their treatment process.See study design

What are the potential side effects?

Since this trial involves management strategies rather than drugs or medical procedures directly affecting the body's biology, there are no direct side effects associated with traditional clinical interventions.

REACH Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with a type of gastrointestinal cancer.

Select...

I am 70 years old or older.

REACH Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Acceptability of electronic fitness assessment questionnaire

Association of geriatric consultation with number of unplanned ED visits/hospitalizations among older adult participants

Feasibility of electronic fitness assessment questionnaire (developed from Comprehensive Geriatric Assessment tool)

REACH Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Intervention Phase - Geriatric Co-ManagementExperimental Treatment1 Intervention

Eligible older adults age 70 and older who score "Pre-Frail" or "Frail" will be randomized 2:1 to be offered to meet with a study geriatrician for geriatric co-management in addition to their standard oncology care. Study geriatrician will assist with management of symptoms, additional comorbidities, polypharmacy, and social/emotional concerns in addition to physical care. Geriatrician can make referrals and recommendations for additional supportive services that may be beneficial for more vulnerable older adult patients.

Group II: Intervention Phase - Standard Oncology CareActive Control1 Intervention

This arm is for those older adult patients (age 70+) who score as "Pre-Frail" or "Frail" in the fitness assessment questionnaire and are NOT randomized to meet with the study geriatrician. These patients will be followed for the duration of the study as they proceed with their usual oncology care. Study team will evaluate a number of different measures and outcomes, the primary one being unplanned emergency and hospital visits during the course of the study.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,079 Previous Clinical Trials

340,723 Total Patients Enrolled

Nadine J McCleary, MD, MPHPrincipal InvestigatorDana-Farber Cancer Institute

1 Previous Clinical Trials

59 Total Patients Enrolled

Media Library

Geriatric Co-Management Clinical Trial Eligibility Overview. Trial Name: NCT04674267 — N/A

Gastrointestinal Cancer Research Study Groups: Intervention Phase - Geriatric Co-Management, Intervention Phase - Standard Oncology Care

Gastrointestinal Cancer Clinical Trial 2023: Geriatric Co-Management Highlights & Side Effects. Trial Name: NCT04674267 — N/A

Geriatric Co-Management 2023 Treatment Timeline for Medical Study. Trial Name: NCT04674267 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the highest number of individuals currently enrolled in this clinical experiment?

"Affirmative. According to the resources hosted on clinicaltrials.gov, this medical trial is actively recruiting participants and was initially posted on January 18th 2022 with its most recent update occurring July 14th 2022. The study seeks 257 individuals from 1 site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Resilience and Equity in Aging, Cancer, and Health (REACH)

Nadine McCleary, MD, MPH 2022. "Resilience and Equity in Aging, Cancer, and Health (REACH)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04674267.

All > Colorectal Cancer Boston > Colon Cancer